{
  "disease_name": "Melanoma",
  "synonyms": [
    "Malignant melanoma",
    "Skin cancer"
  ],
  "summary": "Melanoma is a type of cancer that develops from melanocytes, the cells that produce melanin. It most commonly occurs in the skin but can also develop in the mouth, intestines, or eye. It is considered the most dangerous type of skin cancer.",
  "causes": [
    "Ultraviolet light (UV) exposure from the sun or tanning devices",
    "DNA damage from UV radiation",
    "Genetic mutations",
    "Mutations in BRAF genes (V600E or V600K)",
    "Mutations in RAS genes (NRAS, HRAS, KRAS)",
    "Loss-of-function mutations in tumor suppressor genes (NF1, TP53, CDKN2A)",
    "Kinase fusions (BRAF, RAF1, ALK, RET, ROS1, NTRK1, NTRK3, MET)",
    "Human endogenous retroviruses (HERV-K) activity"
  ],
  "risk_factors": [
    "Low levels of skin pigment melanin",
    "Many moles",
    "History of affected family members",
    "Poor immune function",
    "Xeroderma pigmentosum",
    "Dysplastic nevus syndrome (familial atypical multiple mole melanoma - FAMMM)",
    "Having more than 50 moles",
    "Weakened immune system",
    "Exposure to UV radiation from tanning beds",
    "Working in airplanes (increased UV exposure)",
    "Fair skin",
    "Red hair",
    "Multiple atypical nevi or dysplastic nevi",
    "Giant congenital melanocytic nevi",
    "Older age (over 50 years old)",
    "Male sex (in the US, occurs 1.6 times more often in men than women)",
    "Living close to the equator",
    "Childhood sun exposure",
    "Multiple severe sunburns",
    "Previous melanoma diagnosis"
  ],
  "symptoms": [
    "Changes in a mole (increase in size, irregular edges, change in color, itchiness, skin breakdown)",
    "Appearance of a new lump on the skin (nodular melanoma)",
    "Itching, ulceration, or bleeding of a mole",
    "Asymmetry",
    "Irregular borders",
    "Variegated color",
    "Diameter greater than 6 mm",
    "Evolving over time",
    "Elevated above the skin surface (nodular melanoma)",
    "Firm to the touch (nodular melanoma)",
    "Growing (nodular melanoma)",
    "Loss of appetite (metastatic melanoma)",
    "Nausea (metastatic melanoma)",
    "Vomiting (metastatic melanoma)",
    "Fatigue (metastatic melanoma)"
  ],
  "diagnosis": [
    "Biopsy of skin lesion",
    "Analysis of skin lesion",
    "Visual inspection of skin lesion",
    "Dermoscopy",
    "Reflectance confocal microscopy",
    "Total body photography",
    "Histological analysis",
    "Breslow scoring",
    "Incisional biopsies (punch biopsies)",
    "Elliptical excisional biopsies",
    "CT scans (for metastasis)",
    "MRIs (for metastasis)",
    "PET/CT scans (for metastasis)",
    "Ultrasound (for metastasis)",
    "Sentinel lymph node biopsy",
    "Lymphoscintigraphy",
    "LDH levels (may be elevated in metastatic melanoma)",
    "Chest X-rays",
    "S-100 protein marker presence",
    "HMB-45 monoclonal antibody reactivity"
  ],
  "treatments": [
    "Surgical removal of melanoma",
    "Removal of adjacent tissue",
    "Testing nearby lymph nodes for spread",
    "Immunotherapy",
    "Biologic therapy",
    "Radiation therapy",
    "Chemotherapy",
    "Surgery (wide local excision, Mohs surgery)",
    "Immune checkpoint inhibitor treatment",
    "High-dose interferon treatment",
    "Dacarbazine",
    "Temozolomide",
    "Fotemustine",
    "Isolated limb infusion (ILI)",
    "Targeted therapy (BRAF inhibitors, MEK inhibitors, C-Kit inhibitors, NRAS inhibitors)",
    "Vemurafenib",
    "Dabrafenib",
    "Trametinib",
    "Encorafenib",
    "Binimetinib",
    "Lifileucel (Amtagvi)",
    "Cytokine therapies (IFN-a, IL-2)",
    "Anti-CTLA-4 monoclonal antibodies (ipilimumab, tremelimumab)",
    "Toll-like receptor (TLR) agonists",
    "CD40 agonists",
    "Anti-PD-1 antibodies (pembrolizumab, nivolumab)",
    "PD-L1 antibodies",
    "Combination therapy (e.g., nivolumab and ipilimumab)",
    "Adoptive cell transfer (ACT)",
    "Tumor-infiltrating lymphocytes (TILs)",
    "Genetically altered autologous lymphocytes with T cell receptors (TCRs)",
    "Cancer vaccine",
    "Oncolytic virotherapy (Talimogene laherparepvec - T-VEC)",
    "Antiretrovirals (lamivudine, doravirine, cabotegravir)",
    "Imiquimod (topical cream)",
    "Topical tazarotene",
    "Kilovoltage x-ray beams (radiation therapy)",
    "Radioimmunotherapy",
    "Palliative care"
  ],
  "related_genes": [
    "BRAF",
    "RAS (NRAS, HRAS, KRAS)",
    "NF1",
    "TP53",
    "CDKN2A",
    "RAF1",
    "ALK",
    "RET",
    "ROS1",
    "NTRK1",
    "NTRK3",
    "MET",
    "MC1R",
    "MDM2 SNP309",
    "MCM6",
    "TIMELESS",
    "WIPI1",
    "EphA2"
  ],
  "subtypes": [
    "Cutaneous melanoma",
    "Uveal melanoma",
    "Mucosal melanoma",
    "Primary pulmonary melanoma",
    "Nodular melanoma",
    "Superficial spreading melanoma",
    "Lentigo maligna melanoma",
    "Acral lentiginous melanoma",
    "Amelanotic melanoma",
    "Desmoplastic melanoma",
    "Melanoma with small nevus-like cells",
    "Melanoma with features of a Spitz nevus",
    "Vaginal melanoma",
    "Polypoid melanoma",
    "BRAF mutant subtype",
    "RAS mutant subtype",
    "NF1 mutant subtype",
    "Triple wild-type subtype"
  ]
}